Literature DB >> 8316219

Enzymatic and pH modulation of mitomycin C-induced DNA damage in mitomycin C-resistant HCT 116 human colon cancer cells.

S S Pan1, F Yu, C Hipsher.   

Abstract

The effect of pH and oxygen on DNA alkylation by mitomycin C (MMC) was studied with cell fractions and intact cells. The cell lines used were the HCT 116 human colon cancer cell line and a MMC-resistant subline (HCT 116-R30A) that has 5% of the quinone reductase activity present in the parent cell line. Microsomal fractions of the two cell lines catalyzed MMC-DNA adduct formation only under anaerobic conditions with equal efficiency. However, the pH of the reaction controlled the production of four identified and two unidentified adducts. Soluble fractions from each cell source catalyzed MMC-DNA adduct formation under aerobic and anaerobic conditions similarly. At higher pH, limited DNA adducts were produced by MMC activated by soluble fractions from either cell source. At lower pH, more DNA adducts were obtained with MMC activated by the soluble fraction of HCT 116 cells than with that activated by the soluble fraction of HCT 116-R30A cells. Four of these adducts were identified as N2-(2" beta,7"-diaminomitosene-1" alpha-yl)-2'-deoxyguanylic acid, N2-(2" beta,7"-diaminomitosen-1" beta-yl)-2'-deoxyguanylic acid, N2-(10"-decarbamoyl-2",7"-diaminomitosen-1" alpha-yl)-2'-deoxyguanylic acid, and N2-(2" beta,7"-diamino-10"-deoxyguanyl-N2-yl-mitosen-1" alpha-yl)-2'- deoxyguanylic acid. Acidic intracellular pH enhanced the cytotoxicity of MMC for HCT 116 cells, decreasing the IC50 from 0.3 +/- 0.04 microM to 0.1 +/- 0.03 microM, but pH had limited effect on the cytotoxicity of MMC for HCT 116-R30A cells. When intracellular pH was decreased, interstrand DNA cross-linking by MMC increased to a greater extent in HCT 116 cells than in HCT 116-R30A cells. Only two DNA adducts, each at low intensity, were detected in HCT 116-R30A cells treated at pH 6.0 and 7.6 and in HCT 116 cells treated at pH 7.6. However, six radioactive spots were detected in HCT 116 cells treated at pH 6.0. Three of these adducts were identified. This is the first direct evidence that acidic intracellular pH enhances MMC-DNA adduct formation in tumor cells containing high quinone reductase activity. Results from this study further confirm that pH and not enzyme is the determining factor in the distribution of types of MMC-DNA adducts. This study also indicates that low intracellular pH enhances the activity of quinone reductase in reducing MMC, which is important for aerobic cytotoxicity of MMC against tumor cells with high concentration of quinone reductase.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8316219

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Mapping DNA adducts of mitomycin C and decarbamoyl mitomycin C in cell lines using liquid chromatography/ electrospray tandem mass spectrometry.

Authors:  Manuel M Paz; Sweta Ladwa; Elise Champeil; Yanfeng Liu; Sara Rockwell; Ernest K Boamah; Jill Bargonetti; John Callahan; John Roach; Maria Tomasz
Journal:  Chem Res Toxicol       Date:  2008-12       Impact factor: 3.739

Review 2.  Enzymology of bioreductive drug activation.

Authors:  D Ross; H D Beall; D Siegel; R D Traver; D L Gustafson
Journal:  Br J Cancer Suppl       Date:  1996-07

3.  Cytotoxic mechanisms of anti-tumour quinones in parental and resistant lymphoblasts.

Authors:  A Halinska; T Belej; P J O'Brien
Journal:  Br J Cancer Suppl       Date:  1996-07

4.  Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures.

Authors:  W C Yen; T Schmittgen; J L Au
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

5.  Dorzolamide synergizes the antitumor activity of mitomycin C against Ehrlich's carcinoma grown in mice: role of thioredoxin-interacting protein.

Authors:  Belal M Ali; Sawsan A Zaitone; Samia A Shouman; Yasser M Moustafa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-08-12       Impact factor: 3.000

Review 6.  NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.

Authors:  David Siegel; Chao Yan; David Ross
Journal:  Biochem Pharmacol       Date:  2011-12-24       Impact factor: 6.100

7.  A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9.

Authors:  G A Choudry; P A Stewart; J A Double; M R Krul; B Naylor; G M Flannigan; T K Shah; J E Brown; R M Phillips
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.